Commercialising science and technology is key to the continued growth of Australia’s vibrant life sciences industry. Translating research into real-world results has important implications for consumers and businesses alike.

Bio Connections Australia 2023 was held today at Crown Promenade Melbourne with an important focus on translation, drug development and expediting Australia’s science into commercialisation.

The forum brought together a diverse mix of leading industry stakeholders: biotechs, pharmaceutical companies, medical technology companies, VCs and other investors alike. As well as, MRIs, CROs, trial sites, universities and clinical trial networks.

Cartherics’ Acting Chief Translational Officer, Dr Frederico Calhabeu attended the forum and said: “I’m very excited to be attending the Bio Connections Australia Forum as it will provide an opportunity to network with industry leaders in the field and discuss how partnering with Cartherics can help develop new treatment options for people with cancer.”

Australia is now well known as a leading destination for early-phase clinical trials. The next step is to ensure we continue to build on these efficiencies and innovations. What are the innovative models which can be adopted and sustained? What are the opportunities with new tech and devices within clinical trials and what are the regulatory considerations? Another important part of the discussion at this event is how biotech companies and researchers can better translate their research into commercial products.

The forum started with a breakfast briefing on ‘Getting the most out of your CRO partnerships’ which was followed by the opening keynote delivered by David Hoey, CEO Vaxxas, titled, ‘Building for Success in Australia. The forum also featured a series of panels covering topics in biotech investment, grant funding, clinical trials, IP, commercialisation, and attracting big pharma to Australian biotech.

Bio Connections Australia discussed the need for ongoing work to drive Australia to become globally competitive in novel therapeutics and create better pathways for companies to translate their research into commercial products.